Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

ALK Inhibitor Shows Promise in Rare, Progressive Tumor Types

2.

The Predictive Power of Liquid Biopsy in Colon Cancer Outcomes Is Inconsistent.

3.

Could CT scans be fueling a future rise in cancer cases, as a new study suggests?

4.

Reducing social media to an hour a day boosts young people's self-image.

5.

Charles III, King of Kings, is Cancerous.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot